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Background: Ensuring adherence to prescribed smoking cessation medications, such as 
Champix® (varenicline), is essential during a quit attempt as non-adherence can significantly 
reduce the likelihood of achieving prolonged smoking abstinence. The use of dose administra-
tion aids may improve adherence, though medication stability on repackaging is not guaranteed, 
due to a lack of available data from manufacturers supporting this practice.
Objective: To determine the suitability for repackaging varenicline tartrate tablets into a dose 
administration aid, by assessing its physical and chemical stability after being repackaged and 
stored at ambient conditions for 6 weeks.
Methods: Varenicline tartrate (1.0 mg) tablets were repackaged into commercially available 
Webster-pak® blister compartments and stored for 42 days at ambient conditions characteristic 
of a Zone IVB climate (30 ± 2°C and 75 ± 5% relative humidity) according to the World Health 
Organization (WHO) guidelines on pharmaceutical stability testing. Physical and chemical 
tests were performed on the repackaged and control tablets, including an assessment of: tablet 
thickness, hardness, weight uniformity, friability, dissolution, disintegration, and content uni-
formity after exposure to ambient conditions and light according to International Council on 
Harmonisation of Technical Requirements of Pharmaceuticals for Human Use guideline Q1B.
Results: Weight, friability, and thickness of the tablets complied with compendial standards. A 
validated high performance liquid chromatography method was used to confirm that after exposure 
to light, and repackaging at 30°C/75% relative humidity, the tablets remained within the required 
95%–105% of the stated drug content. However, tablet hardness and disintegration decreased over 
time, with tablets becoming softer and undergoing more rapid disintegration in water. 
Conclusion: Repackaging 1.0 mg varenicline tartrate tablets into a dose administration aid 
can be undertaken to improve adherence rates and therefore smoking abstinence rates. This 
can be performed without compromising either the physical or chemical stability of the tablets.
Keywords: stability, compliance, degradation
Introduction
Medication adherence is an under-addressed area in health care, with approximately 
50% of patients with a chronic illness not taking their prescribed regimens as directed.1,2 
As advancements in pharmacotherapeutics mean little if patients do not adhere to 
their prescribed regimen, increasing medication adherence through a combination 
of patient and physician-based interventions will likely have a significant effect on 
medical outcomes.3,4 Poor medication adherence to smoking cessation aids has been 
a long-standing problem in combating tobacco use, including for the most effective 
smoking cessation aid Champix® ([1.0 mg varenicline tartrate] Pfizer, Inc., New York, 
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NY, USA), which requires at least 3 months of therapy to 
effectively support a quit attempt.5 Research into varenicline 
adherence has found a correlation between prolonged smok-
ing abstinence and adherence to the prescribed varenicline 
regimen.6,7 
Dose administration aids (DAAs) are one potential avenue 
to increase medication adherence, as they can simplify 
complex regimens by repackaging medications into easily-
followed compartmentalized devices.8,9 The elderly, those 
with mental illnesses, and those on multiple medications may 
benefit from the increased convenience and reduced error 
associated with DAA use. However, there are some issues 
associated with DAAs, primarily that some medications 
cannot be physically stored together due to surface interac-
tions, and the risk of compromised physical and/or chemical 
stability.10 Exposure to heat, humidity, oxygen, and light can 
all contribute to physical degradation of the dosage form 
and/or chemical degradation of the active pharmaceutical 
ingredient or excipients in the medication. Medication sta-
bility guarantees by manufacturers are also invalidated upon 
removal from the original packaging, meaning an informed 
decision is required to be made by health professionals prior 
to committing to repackaging medications into a DAA.8-11 
Webster-pak® is a commonly utilized DAA device in com-
munity pharmacies in Australia, though they are often used 
without the availability of published data on the stability of 
individually repackaged medications. Commonly used and 
repackaged medications such as aspirin, atenolol, furosemide, 
and sodium valproate have all been reported to demonstrate 
physical or chemical instability upon repackaging.12-17 The 
objective of this research was thus to determine the physical 
and chemical stability of varenicline tartrate, when repack-
aged into a DAA and stored under ambient temperature and 
humidity conditions in order to recommend its suitability for 
repackaging in clinical practice.
Methods
Conditions
To determine whether commercial varenicline tartrate tablets 
are suitable for repackaging, tests were performed to iden-
tify any issues in relation to physical or chemical stability 
between the repackaged and control tablets. Varenicline 
tablets were purchased from a local pharmacy, removed from 
their original packaging, and repackaged individually into 
Multi Dose Webster-pak blister compartments. Gloves and 
plastic packing tweezers were used to handle tablets, and all 
tablets had a remaining shelf-life of at least 9 months at the 
time of sampling.
The DAAs were stored at ambient conditions (30 ± 2°C 
and 75 ± 5% relative humidity) for a period of 42 days in 
a KBF 720 Climate Chamber (Binder GmbH, Tuttlingen, 
Germany). Control tablets were removed from their original 
packaging immediately prior to analysis. A duration of 42 
days was chosen as the results of this study are required prior 
to conducting a randomized controlled trial in which partici-
pants are to be given varenicline tartrate tablets repackaged 
in Webster-pak blister compartments. This duration complies 
with the Pharmaceutical Society of Australia guidelines which 
recommend a maximum repackaged duration of 8 weeks.18
Physical stability testing
Weight uniformity, physical appearance, thickness, hard-
ness, friability, dissolution and disintegration rates were all 
evaluated according to the British Pharmacopeia compendial 
requirements. Weight uniformity was tested by individually 
weighing 20 tablets on an AND HM-200 analytical balance. 
Thickness and hardness of ten tablets were measured using 
a Vankel VK200 instrument, the disintegration of six tablets 
was assessed using a Varian VK100 disintegration apparatus, 
and friability testing of 20 tablets was performed using a 
Vankel Friabilator.19
Dissolution was measured for six tablets using a Vankel 
VK7000 dissolution apparatus with a 100 mL vessel by plac-
ing a 1.0 mg varenicline tartrate tablet in 100 mL of reverse 
osmosis water (pH 5.2) at 37 ± 0.5°C. The rotating paddle 
was set to 100 r/min, and samples withdrawn at 0 and 45 
minutes. Samples were assessed for drug content using high 
performance liquid chromatography (HPLC) (see following 
section). The dissolution results were analyzed using a two-
tailed Mann-Whitney U test (p = 0.05), performed with IBM 
SPSS Statistics Version 23 (IBM Corp., Armonk, NY, USA). 
Chemical stability testing
Varenicline tartrate content was measured using an HPLC 
method validated for specificity, linearity, accuracy, and pre-
cision as per the International Council on Harmonisation of 
Technical Requirements of Pharmaceuticals for Human Use 
(ICH) guideline Q2/R1.20 A Nexera-i LC-2040C 3D liquid 
chromatograph was used to perform content analysis on 
samples, using a mobile phase composed of 12% acetonitrile, 
88% water, and 0.1% formic acid. An XSelect HSS T3 5 µm 
(4.6 mm × 250 mm) column was used with a flow rate of 
1 mL/min, heated to 40°C. The detection wavelength was set 
at 237 nm, and the injection volume at 10 µL. 
Photostability testing involved placing 20 tablets in a 
Webster-pak within a Heraeus Suntest CPS+ with a Solar 
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ID65 filter and irradiating at 500 watt/m2 for 10.6 hours, 
equating to 1.2 million lux hours of exposure to visible light, 
and 496 WH/m2 of ultraviolet light. This is in accordance with 
minimum exposure requirements in ICH guideline Q1B.21 A 
control of 20 tablets (wrapped in aluminum foil) was used 
to determine the effect of temperature. Content analysis was 
conducted on control samples, covered and exposed photosta-
bility samples, and samples from the tablets stored at ambient 
conditions. Samples were prepared by crushing 20 tablets 
in a mortar and pestle, weighing out an amount of powder 
equivalent to one varenicline tartrate tablet, and dissolving in 
water. Samples were filtered through a Millex-GP 0.22 µm 
polyethersulfone-membrane express filter and analyzed by 
HPLC using a calibration curve in the range of 0 to 20 µg/L. 
Results
Physical stability
Tablet appearance did not change after storage under ambient 
conditions, or after exposure to visible and ultraviolet light, 
with each tablet retaining their blue hue and oblong shape. 
A minor increase in tablet weight and thickness occurred after 
storage at ambient temperature and humidity, with the aver-
age tablet weight increasing by 1%, and average tablet thick-
ness increasing by 4%. Significant changes in tablet hardness 
occurred, with the mean pressure to break the control tablets 
being 151 N, which decreased by 27% after storage at ambi-
ent conditions, to an average of 110 N. These changes led 
to brief adhesion to the sides of blister cells, though tablets 
dislodged quickly when moving the DAA, and did not cause 
any visual residue on the sides of the blister cells.
Disintegration times were also reduced, with control tab-
lets disintegrating in 79 seconds, compared to 66 seconds for 
the ambient tablets, a reduction of 16%. Figure 1 illustrates 
the changes in hardness and disintegration times and the 
relationship between these two physical characteristics. Fri-
ability testing resulted in a small amount of weight gain per 
tablet in both groups, with tablets in the control group gain-
ing an average of 85 µg, compared to 260 µg in the ambient 
group. Tablet dissolution was unaffected by the repackaging 
process, with samples taken after 45 minutes averaging 92% 
of drug content dissolved for the control tablets, and 93% for 
the tablets stored at ambient conditions (p = 0.887).
Chemical stability
Content analysis results of the covered tablets and the tablets 
exposed to light, and control tablets and those stored at ambi-
ent conditions (30°C/75% relative humidity) were all within 
the requirements of the compendial standard. There was no 
 significant difference in varenicline tartrate content between 
the four groups. Table 1 displays the content averages and 95% 
confidence intervals for the samples taken from the tablets 
within each group. 
Discussion
Ensuring the physical and chemical stability of medications 
is essential when attempting to reduce patient error and 
improve medication adherence by repackaging into a DAA 
such as a Webster-pak.8-12 Varenicline tartrate content was not 
affected by repackaging and storage for 6 weeks at the worst 
temperature and humidity conditions for long-term stability 
testing recognized by the WHO.22 Though the 0.5 mg var-
enicline tablets were not tested, it is not believed their results 
would differ from the 1.0 mg tablets, as the only excipient 
difference is the coloring agent, and their duration of use in 
varenicline therapy is only 7 days at the beginning of therapy, 
minimizing their duration in the DAA.
Tablet hardness and disintegration times, although sig-
nificantly affected, did not result in compromised physical 
stability of the dosage form or chemical stability of the drug. 
Commercially available varenicline tartrate tablets are pack-
Figure 1 Variation in 1.0 mg varenicline tartrate tablet disintegration times (bars) 
and hardness (dotted line) between control tablets, and tablets stored at ambient 
conditions for 6 weeks. 
Note: Error bars represent 95% confidence intervals about the mean for n = 10 
samples.
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Table 1 Content with 95% confidence intervals (CIs) for 1.0 mg 
varenicline tartrate control tablets compared with those exposed 
to ambient temperature and humidity, and those exposed to light
Storage conditions Photostability conditions
Control % Ambienta % Covered % Exposedb %
99.3  
(CI 97.4–101.2)
100.5  
(CI 96.8–104.2)
100.9  
(CI 95.6–106.2)
100.4  
(CI 99.0–101.8)
Notes: α = 30 ± 2°C and 75 ± 5% relative humidity for 42 days; β = 1.2 million lux 
hours visible light and 496 WH/m2 ultraviolet light.
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aged in small, individual compartments with an aluminum 
backing within a cardboard sleeve, allowing significant 
protection from light, oxygen, and moisture. The Consumer 
Medicine Information leaflet also recommends storing the 
tablets in a cool, dry place below 30°C, specifically mention-
ing not to store them in the bathroom, near a sink, in the car, 
or on a window sill, and not to remove tablets from their 
packaging until a dose is needed.23,24
A retrospective study of a cohort of 1,477 patients in a 
community-based setting found that zero and partial (<80%) 
adherence had similar cessation rates (31.2% and 27.8%) 
respectively, whereas those who exhibited full adherence 
attained cessation rates of 50.7%.6 A similar result was seen 
in the COMPASS Smoking Cessation Intervention Trial, 
with good adherence (>80%) being associated with a 52% 
cessation rate at 6 months, compared to poor adherence, 
which resulted in a 25% cessation rate.7 Poor adherence (and 
premature medication discontinuation) is often attributed to 
adverse effects, as well as smokers either having a perceived 
lack of efficacy or need for the medication.5,25
While Webster-pak blister compartments assist in adher-
ence when using multiple medications through the repackag-
ing of tablets into individual compartments protected by an 
aluminum backing, the lack of a cardboard sleeve and the 
presence of a larger internal area for oxygen and moisture 
result in an increased exposure to light, oxygen, and mois-
ture. An issue not addressed in this study is the potential for 
surface interactions between multiple medications packaged 
within the same blister compartment. Whilst individual var-
enicline tartrate tablets can be safely repackaged into their 
own Webster-pak blister compartments, further research is 
required to assess this effect in other forms of DAAs. There 
is also the need to assess the likelihood of surface interactions 
and subsequent degradation of either varenicline or other 
medications in contact with each other.
Conclusion
The DAA utilized in this study is one of the most commonly 
used in Australia, with pharmacists often seeking evidence-
based recommendations on safe repackaging practices, 
as manufacturer assurances on stability are invalidated 
through repackaging. This is needed for both long-term and 
short-term medications, and those with unusual loading or 
unloading periods, such as varenicline tartrate. This study 
shows that 1.0 mg varenicline tartrate tablets repackaged 
in a Webster-pak will remain stable for a reasonable in-use 
period of 6 weeks when stored appropriately in tropical 
climates. 
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